SCHEMBL14869324

SCHEMBL14869324

Cc1nc(N)nc(NCCc2ccoc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.44
CA2 P00918 5/20 0.44
CA9 Q16790 5/20 0.44
HTR7 P34969 3/20 0.41
ADRA1D P25100 1/20 0.41
HTR2C P28335 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
HTR6 P50406 1/20 0.41
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
APP P05067 1/20 0.36
PIM1 P11309 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK2 Q92630 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
CDK9 P50750 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14869686 0.90 CA1 (0.52) CA1CA2CA9HTR7ADRA1D
SCHEMBL14869660 0.86 CA1 (0.49) CA1CA2CA9HTR7ADRA1D
SCHEMBL1938196 0.80 HTR7 (0.56) CA1CA2CA9HTR7ADORA3
SCHEMBL14869694 0.78 CA1 (0.51) CA1CA2CA9APPCNR2
SCHEMBL14869622 0.76 CA1 (0.49) CA1CA2CA9ADORA2AAPP
SCHEMBL14869377 0.75 ADORA2A (0.51) CA1CA2CA9ADORA3ADORA2A
Bicarbonate SCHEMBL1939053 0.75 HDAC1 (0.54) CA1CA2CA9HTR7ADORA3
SCHEMBL14869691 0.74 CA1 (0.54) CA1CA2CA9HTR7CNR2
SCHEMBL14869316 0.74 ALPL (0.50) CA1CA2CA9HTR7ADRA1D
SCHEMBL15100685 0.74 CA1 (0.38) CA1CA2CA9HTR7ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2941245-B1 DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE ANJI PHARMACEUTICALS INC (US) 2024-06-26 EP disclosed
US-11759441-B2 Biguanide compositions and methods of treating metabolic disorders ANJI PHARMACEUTICALS INC. (US) 2023-09-19 US disclosed
US-11759441-B2 Biguanide compositions and methods of treating metabolic disorders ANJI PHARMACEUTICALS INC. (US) 2023-09-19 US disclosed
US-20230285330-A9 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS ANJI PHARMACEUTICALS INC. 2023-09-14 US disclosed
US-20230285330-A9 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS ANJI PHARMACEUTICALS INC. 2023-09-14 US disclosed
US-20220151957-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ANJI PHARMACEUTICALS INC. 2022-05-19 US disclosed
US-11065215-B2 Biguanide compositions and methods of treating metabolic disorders ANJI PHARMA (US) LLC (US) 2021-07-20 US disclosed
EP-2800561-B1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ANJI PHARMA US LLC (US) 2020-08-19 EP disclosed
US-10668031-B2 Biguanide compositions and methods of treating metabolic disorders ANJI PHARMA (US) LLC (US) 2020-06-02 US disclosed
US-20200138751-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ANJI PHARMACEUTICALS INC. 2020-05-07 US disclosed
WO-2014107617-A1 DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE ELCELYX THERAPEUTICS, INC. (US) 2014-07-10 WO disclosed
US-20140193498-A1 Compositions and Methods for Treating Metabolic Disorders ANJI PHARMACEUTICALS INC. 2014-07-10 US disclosed
US-20140193498-A1 Compositions and Methods for Treating Metabolic Disorders ANJI PHARMACEUTICALS INC. 2014-07-10 US disclosed
WO-2014011926-A1 COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK ELCELYX THERAPEUTICS, INC. (US) 2014-01-16 WO disclosed
US-20130177604-A1 Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 US disclosed
US-20130177604-A1 Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 US disclosed
WO-2013103919-A2 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 WO disclosed
WO-2013103384-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS ELCELYX THERAPEUTICS, INC. (US) 2013-07-11 WO disclosed
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-04-18 US disclosed
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders ELCELYX THERAPEUTICS, INC. (US) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10668031-B2 Biguanide compositions and methods of treating metabolic disorders SLC5A2, SLC5A1, GPR119 CA1 3461/4885CA2 1106/4885CA9 640/4885
US-11065215-B2 Biguanide compositions and methods of treating metabolic disorders SLC5A2, SLC5A1, GPR119 CA1 3461/4885CA2 1106/4885CA9 640/4885
US-20130095140-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders SLC5A2, SLC5A1, GPR119 CA1 3461/4885CA2 1106/4885CA9 640/4885
US-11759441-B2 Biguanide compositions and methods of treating metabolic disorders SLC5A2, SLC5A1, GPR119 CA1 3461/4885CA2 1106/4885CA9 640/4885
US-20130177604-A1 Compositions and Methods of Treating Metabolic Disorders FABP2, GPR119, PNLIP CA1 4452/4885CA2 2254/4885CA9 1691/4885
US-20140193498-A1 Compositions and Methods for Treating Metabolic Disorders SLC5A2, SLC10A1, GPR119 CA1 4492/4885CA2 1680/4885CA9 871/4885
US-20220151957-A1 BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS SLC5A2, SLC5A1, GPR119 CA1 3461/4885CA2 1106/4885CA9 640/4885
US-20230285330-A9 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS FABP2, GPR119, PNLIP CA1 4463/4885CA2 2345/4885CA9 1540/4885
US-20200138751-A1 Biguanide Compositions and Methods of Treating Metabolic Disorders SLC5A2, SLC5A1, GCG CA1 3320/4885CA2 1136/4885CA9 589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.